Tempus AI (TEM) Q2 2026 earnings — TrendMatrix coverage
Reported
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Full disclosure
Key numbers
- Adjusted EPS
- -$0.04
- Estimate
- -$0.15
- Surprise
- +73.6%
- Revenue (period 2026-06-30)
- $382.5M
- Score today
- 4.8/10
Revenue source: xbrl.
How the report landed
Tempus AI (TEM) reported a narrower loss than forecast — adjusted EPS of -$0.04 against the -$0.15 estimate (a 73.6% beat on a still-unprofitable quarter).
Where TrendMatrix's rating stands now
TrendMatrix currently rates TEM Sell at 4.8/10; no pre/post engine snapshot brackets this report.
4 of the last 4 quarters beat the estimate; this quarter's +73.6% surprise compares with a +42.2% four-quarter average. Next scheduled report: 2026-11-03.
What argues against it
- Concentration risk — Product: oncology and hereditary tests (74.0%)
- Concentration risk — Supplier: sole suppliers
- Target reached (-3.1% upside)
This section and the ones below it reflect TrendMatrix’s latest engine read — they update after the report date and are not frozen to it.
The levels TrendMatrix's engine tracks
- Current price
- $68.32
- Price target
- $87.31
- Stop
- $64.18
- Upside to target
- +27.8%
Model outputs from TrendMatrix’s engine as of 2026-10-15 — shown for context, not personalized investment advice.
TEM at TrendMatrix's latest read
Healthcare earnings trade on pipeline and payer dynamics as much as the quarter itself; a beat or miss is weighed against trial and reimbursement news.
- Industry
- Health Information Services
- Market cap
- $12.31B
- P/E (fwd)
- -1365.5
- 52-week range
- $40.77–$97.25
- Off 52-week high
- 29.7%
- RSI (14)
- 32
- Volume vs avg
- 0.79×
- Score today
- 4.8/10